SCHEMBL2404886

SCHEMBL2404886

COc1ccc2[nH]cc(CC(=O)N(C)C3CC3)c2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.64
KMT2A Q03164 3/20 0.57
MTNR1A P48039 7/20 0.55
MTNR1B P49286 6/20 0.55
ALDH1A1 P00352 2/20 0.55
GPR84 Q9NQS5 1/20 0.54
CYP2D6 P10635 3/20 0.54
HTR2B P41595 3/20 0.54
CYP1A2 P05177 3/20 0.54
HTR1A P08908 3/20 0.54
HTR1D P28221 2/20 0.54
HTR1B P28222 2/20 0.54
HTR2A P28223 2/20 0.54
HTR2C P28335 2/20 0.54
HTR7 P34969 2/20 0.54
HTR6 P50406 2/20 0.54
HTR4 Q13639 2/20 0.54
HTR3E A5X5Y0 1/20 0.54
HTR3B O95264 1/20 0.54
CYP2C9 P11712 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30418868 1.00 KDM4E (0.64) KDM4EKMT2AMTNR1AMTNR1BALDH1A1
SCHEMBL25284215 0.97 KDM4E (0.62) KDM4EKMT2AMTNR1AMTNR1BALDH1A1
SCHEMBL31473497 0.95 KDM4E (0.58) KDM4EKMT2AMTNR1AMTNR1BALDH1A1
SCHEMBL2405107 0.91 MAPT (0.54) KDM4EKMT2AMTNR1AMTNR1BALDH1A1
SCHEMBL30418875 0.90 KDM4E (0.60) KDM4EKMT2AMTNR1AMTNR1BALDH1A1
SCHEMBL25236941 0.90 KDM4E (0.60) KDM4EKMT2AMTNR1AMTNR1BALDH1A1
SCHEMBL24496999 0.85 KDM4E (0.73) KDM4EKMT2AMTNR1AMTNR1BALDH1A1
SCHEMBL29992041 0.85 KDM4E (0.73) KDM4EKMT2AMTNR1AMTNR1BALDH1A1
SCHEMBL29993218 0.85 KDM4E (0.73) KDM4EKMT2AMTNR1AMTNR1BALDH1A1
SCHEMBL2403274 0.84 ICMT (0.49) KDM4EKMT2AMTNR1AMTNR1BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074873-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-03-06 US disclosed
EP-4452938-A1 COMPOUNDS Psylo Pty Ltd (AU) 2024-10-30 EP disclosed
WO-2023115167-A1 COMPOUNDS Psylo Pty Ltd (AU) 2023-06-29 WO disclosed
WO-2023115167-A1 COMPOUNDS Psylo Pty Ltd (AU) 2023-06-29 WO disclosed
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074873-A1 COMPOUNDS NLN, SLC18A2, PYGB KDM4E 3243/4885KMT2A 2336/4885MTNR1A 888/4885
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES HCRTR2, HCRTR1, HRH3 KDM4E 452/4885KMT2A 253/4885MTNR1A 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.